Copertina

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Michal Jirásko, Roman Viták, Ladislav Pecen, Andrea Pinkeová, Jan Tkáč, Tomáš Bertók, Natalie Bergman, Radek Kučera
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Serum Levels of Prostate Specific Antigen, Free PSA, [‐2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions
di: Yitong Weng, et al.
Pubblicazione: (2025)

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
di: Mike Wenzel, et al.
Pubblicazione: (2024)

Altered Glycosylation of PSA in Prostate Cancer Tissue
di: Hannu Koistinen, et al.
Pubblicazione: (2025)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
di: Eli Marie Grindedal, et al.
Pubblicazione: (2024)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
di: Anwar E. Ahmed, et al.
Pubblicazione: (2025)

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
di: Irena Abramovic, et al.
Pubblicazione: (2024)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA
di: Penglu Yang, et al.
Pubblicazione: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
di: Nicholas Fedele, et al.
Pubblicazione: (2025)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
di: Mark Kidd, et al.
Pubblicazione: (2025)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
di: Liza M. Kurucz, et al.
Pubblicazione: (2025)

PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 Lesions
di: Ali Ayranci, et al.
Pubblicazione: (2024)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
di: Takanori Tokunaga, et al.
Pubblicazione: (2025)

A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening
di: Jian Gu, et al.
Pubblicazione: (2024)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
di: Chris H.‐M. Wong, et al.
Pubblicazione: (2024)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
di: Takeshi Tsutsumi, et al.
Pubblicazione: (2026)

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
di: Hikari Miura, et al.
Pubblicazione: (2025)

Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique
di: Andrea Romei, et al.
Pubblicazione: (2025)

Cáncer de Próstata. ¿Qué es el antígeno prostático específico?. (La biología del PSA)
di: Juan Fernando Uribe Arcila
Pubblicazione: (2007)

Performance of large language models on benign prostatic hyperplasia frequently asked questions
di: YuNing Zhang, et al.
Pubblicazione: (2024)

Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review
di: Ahmad Abid, et al.
Pubblicazione: (2024)

Responses to queries concerning “Performance of large language models on benign prostatic hyperplasia frequently asked questions”
di: YuNing Zhang, et al.
Pubblicazione: (2024)

Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS)
di: Dana Cavanaugh, et al.
Pubblicazione: (2024)

What are we missing? Identifying clinically significant prostate cancer among patients with low PSA : the utility of the free‐to‐total PSA ratio
di: Daniel Crisafi, et al.
Pubblicazione: (2025)

Utility of PSA free‐to‐total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL
di: Samuel Sii, et al.
Pubblicazione: (2024)

Beyond the PSA: The hidden costs of screening in prostate cancer
di: Chiranjeev Sanyal, et al.
Pubblicazione: (2024)

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
di: Kamil Malshy, et al.
Pubblicazione: (2024)

Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy
di: Thomas Büttner, et al.
Pubblicazione: (2024)

Targeting proliferating cell nuclear antigen enhances ionizing radiation‐induced cytotoxicity in prostate cancer cells
di: Shan Lu, et al.
Pubblicazione: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
di: Eric V. Li, et al.
Pubblicazione: (2024)

PSA ¿Si o No?
di: Juan Fernando Uribe Arcila
Pubblicazione: (2008)

Editorial Comment on Beyond Total PSA : Clinical Significance of S2 , 3PSA % in Reducing Unnecessary Prostate Biopsies
di: Yusuke Goto
Pubblicazione: (2026)

Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
di: Zain Abedali, et al.
Pubblicazione: (2024)

Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer
di: Andrew W. Silagy, et al.
Pubblicazione: (2025)

Do Prostate Imaging‐Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
di: Kyle Tsai, et al.
Pubblicazione: (2024)

Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer
di: Shingo Ashida, et al.
Pubblicazione: (2024)

Systematic review of PSA reference intervals in the gender diverse population with prostates
di: Rose Hall, et al.
Pubblicazione: (2025)

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
di: Andrea K. Miyahira, et al.
Pubblicazione: (2024)

Diagnosis and management of neuroendocrine prostate cancer
di: Ivan de Kouchkovsky, et al.
Pubblicazione: (2024)